Biography:Russell J. Howard

From HandWiki
Russell J. Howard
Born
Australia
NationalityAustralian
Known forMalaria Research, Biotechnology Industry
AwardsAdvance Global Australian Award, Overall winner and Biotechnology Award, 2013[1]
Scientific career
FieldsBiotechnology
InstitutionsNIH, DNAX Schering Plough, Maxygen, GSK, Affymax, NovoNutrients, Garvan Institute of Medical Research, Immutep, NeuClone,

Russell J. Howard is an Australian-born executive, entrepreneur and scientist. He was a pioneer in the fields of molecular parasitology, especially malaria,[2][3][4][5][6] and in leading the commercialisation of one of the most important methods used widely today in molecular biology today called “DNA shuffling" or "Molecular breeding",[7] a form of "Directed evolution".

His contributions to malaria research over an 18-year period began in Australia at the Walter and Eliza Hall Institute of Medical Research, then continued as a tenured Principal Investigator at the National Institutes of Health (NIH) in Bethesda, MD, USA, and continued at the biotechnology companies DNAX (now Schering-Plough Biopharma) and Affymax in California. Thirteen years of his group's malaria research on antigenic variation in malaria[2][3][4][5][6][8][9][10][11][12][13][14][15][16][17][18] culminated in the first molecular cloning of the malarial antigen PfEMP1,[19] a parasite protein that this human malaria parasite expresses on the surface of malaria-infected red cells[4][5][20] This antigen represents critical biological functions for the parasite including immune evasion and adherence to microvascular endothelial cells.[21] During this time, Howard served on the World Health Organization's Special Program for Research and Training in Tropical Diseases and the USAID program for research and vaccine development in malaria.[citation needed]

While Howard was President and Scientific Director at Affymax Research Institute, Willem 'Pim' Stemmer[22] conceived and developed DNA shuffling Technology.[7] This revolutionary technology for improving the expressed phenotype of genes, pathways, plasmids, viruses and genomes gave birth to the creation and spinout of Maxygen Inc.[23] where Howard was CEO for 12 years (1997-2009).

He took the company public in 1999[24] and led its growth with 10's of corporate partnerships and technology application programs that led ultimately to the development and commercialisation worldwide of 10's of Life Science products in diverse fields. Maxygen exploited DNA Shuffling technology across the entire Life Sciences spectrum, creating new companies dedicated to Agricultural Products (Verdia[25]) and Industrial Chemical opportunities (Codexis[26]) as well as a Protein Pharmaceuticals Business (Perseid[27]).

In 2008, Howard left Maxygen to found Oakbio Inc. in 2009. He remains Chairman of Oakbio Inc. (doing business as NovoNutrients Inc.), in Sunnyvale, California, USA. NovoNutrients uses proprietary microbes for CO
2 capture from industrial processes. Industrial CO
2 emissions are used as sole carbon source and H2 gas as sole energy source to manufacture bacterial biomass, or single cell protein, a source of high quality protein for aquaculture and in future, for human foods [1].

Upon taking up residence in 2012 in Sydney, Australia, Howard became Executive Chairman of NeuClone Pty. Ltd., a clinical stage biotechnology company dedicated to development of biosimilars of monoclonal antibody drugs.

In 2013 Howard joined Prima Biomed Pty. Ltd., based in Sydney, Berlin and Paris, later renamed Immutep Pty. Ltd., as Non-Executive Director. In 2017 he took the role of Non-Executive Chairman and continues today in this role. Immutep develops novel immuno-oncology and autoimmune drugs based on its LAG3 patent estate.

He was Commercial Strategy Advisor at the Garvan Institute of Medical Research's Kinghorn Centre for Clinical Genomics in Sydney, 2015–2018.[28][29]

Howard has published over 145 scientific publications in refereed journals and is an inventor on nine issued patents.

Education

Howard graduated from Box Hill High School in Melbourne, Australia and later majored in Chemistry and Biochemistry at the University of Melbourne, culminating in a PhD in 1975 where he studied the carbohydrate and central metabolism of Caulerpa simpliciuscula, a marine green alga.[30]

Employment

He spent his first postdoctoral studies from 1976 to 1979 at the Immunoparasitology Laboratory at the Walter & Eliza Hall Institute in Melbourne, with frequent visits and collaborative work on sialic acids at the Biochemisches Institut at Christian Albrechts Universitat in Kiel, Germany. He started working as a Research Associate in the Malaria Section of the National Institutes of Health in Bethesda, Maryland before earning his tenure in the same institution in 1987. From 1988 to 1992, he worked at the Laboratory of Infectious Diseases of the DNAX Research Institute of Molecular and Cellular Biology in Palo Alto, California, USA, with dual roles, studying cytokine genes for Schering Plough, the parent organisation of DNAX Research Institute, and leading his Infectious Diseases laboratory there on malaria work funded by DNAX and USAID.[31]

In 1994, he was named President and Scientific Director of Affymax, Inc. where he managed teams working on small molecule drug lead discovery using combinatorial chemistry and high throughput target screening. His independent malaria work continued at Affymax with support from USAID and Affymax, leading to cloning of the PfEMP1 gene while at Affymax.[19] After Affymax was purchased by GlaxoWellcome, Howard led technology transfer and interchange in combinatorial chemistry, drug discovery and optimisation between Affymax and GlaxoWellcome worldwide. During this time, Molecular breeding or DNA shuffling Technology was conceived[7] and the nascent company Maxygen Inc. incubated for later spun out from Affymax-GlaxoWellcome.[23]

From 1997 to 2009, Howard worked as Maxygen's CEO, focusing on human, including, protein pharmaceutical drugs and vaccine discovery, as core business. Non-core businesses were successively incubated, nurtured and spun-out (Codexis[26]) or sold (Verdia[25]). In 2008, he left Maxygen with $200MM in cash, no debt, on-going clinical stage drug development programs and multiple partnerships and licenses with other parties.

Following his departure, Howard started Oakbio, Inc., doing business as NovoNutrients Inc, a privately held Clean Technology company in Sunnyvale, California, USA. NovoNutrients captures CO2 from industrial waste gas streams and uses microbial chemosynthetic systems to capture and convert this carbon resource to protein-rich microbial biomass and valuable chemicals, sequestering a Green House Gas from accumulation in the atmosphere.

In 2012 Howard moved residency from Silicon Valley, California, where he had worked for 25 years, to Sydney, Australia.

From Sydney, Howard acts as Executive Chairman of NeuClone, Non-Executive Chairman of Immutep and Chairman of NovoNutrients.

Financing leadership

With Howard as CEO, Maxygen, Inc. completed its initial public offering of $110MM in 1999, just two years after its spinout from Affymax-GlaxoWellcome.[24] In March 2000, Maxygen raised another $150MM in a Secondary Public Offering. More recently, Howard and colleagues at NeuClone, Pty. Ltd. raised >$10 MM (AUS) from private investors in Sydney to support development of a portfolio of 10 biosimilar monoclonal antibodies.

Recognition & research

Howard has been awarded three Doctor of Science (honoris causa) degrees, one from the University of Technology, Sydney, Australia in 2004, one from the University of Queensland, Brisbane, Australia in 2008 and the third from the University of Melbourne, Melbourne, Australia in 2014. He was awarded the inaugural Grimwade Medal for Biochemistry, Department of Biochemistry & Molecular Biology, University of Melbourne, in 2016. Howard's >145 publications tackle topics ranging from the metabolism of the algae Caulerpa simpliciuscula, to the molecular pathogenesis of human cerebral malaria and the role of parasite antigenic variation and infected cell adherence in disease virulence. His papers reflect successful use of the tools of biochemistry, protein chemistry and structure-function, molecular biology, cell biology, large animal studies, and field studies with humans.

Patents

Howard is an inventor on nine patents. At the NIH he patented discovery, characterisation and cloning of a novel gene encoding a soluble malarial antigen, called PfHRP2[32] that the most lethal human malaria releases into the blood. This discovery led to a rapid, sensitive, inexpensive and reliable diagnostic test for malaria infection that the NIH licensed commercially.[33] This test has been used worldwide for over 15 years.[34] In 1990 and 1995, he and his colleagues at Affymax applied for the patents of antigenic determinants obtained using a pathogenic agent or a derivative that presents a restricted set of antigens, and recombinant DNA clone from Plasmodium falciparum. While working at Maxygen Inc., he and his colleagues developed three patents for the following technologies: antigen library immunisation using polynucleotides encoding flavivirus and alphavirus; multivalent antigenic polypeptides; and optimisation of immunomodulatory properties of genetic vaccines

Selected references and publications

  1. ↑ "Russell Howard". https://www.advance.org/russell-howard/. 
  2. ↑ 2.0 2.1 Howard, Russell J. (January 1982). "Alterations in the Surface Membrane of Red Blood Cells During Malaria". Immunological Reviews 61 (1): 67–107. doi:10.1111/j.1600-065x.1982.tb00374.x. PMID 6174414. 
  3. ↑ 3.0 3.1 Howard, R. J.; Barnwell, J. W.; Kao, V. (1 July 1983). "Antigenic variation of Plasmodium knowlesi malaria: identification of the variant antigen on infected erythrocytes.". Proceedings of the National Academy of Sciences 80 (13): 4129–4133. doi:10.1073/pnas.80.13.4129. PMID 6191331. Bibcode: 1983PNAS...80.4129H. 
  4. ↑ 4.0 4.1 4.2 Leech, J H; Barnwell, J W; Miller, L H; Howard, R J (1 June 1984). "Identification of a strain-specific malarial antigen exposed on the surface of Plasmodium falciparum-infected erythrocytes.". Journal of Experimental Medicine 159 (6): 1567–1575. doi:10.1084/jem.159.6.1567. PMID 6374009. 
  5. ↑ 5.0 5.1 5.2 Howard, RJ (13 November 1984). "Antigenic variation of bloodstage malaria parasites". Philosophical Transactions of the Royal Society of London. B, Biological Sciences 307 (1131): 141–158. doi:10.1098/rstb.1984.0115. PMID 6151679. Bibcode: 1984RSPTB.307..141H. 
  6. ↑ 6.0 6.1 Aley, S B; Sherwood, J A; Howard, R J (1 November 1984). "Knob-positive and knob-negative Plasmodium falciparum differ in expression of a strain-specific malarial antigen on the surface of infected erythrocytes.". Journal of Experimental Medicine 160 (5): 1585–1590. doi:10.1084/jem.160.5.1585. PMID 6208311. 
  7. ↑ 7.0 7.1 7.2 Stemmer, Willem P.C. (2002). "Molecular Breeding of Genes, Pathways and Genomes by DNA Shuffling". The Scientific World Journal 2: 130–131. doi:10.1100/tsw.2002.61. PMID 29973836. 
  8. ↑ Leech, J H; Barnwell, J W; Aikawa, M; Miller, L H; Howard, R J (1 April 1984). "Plasmodium falciparum malaria: association of knobs on the surface of infected erythrocytes with a histidine-rich protein and the erythrocyte skeleton.". Journal of Cell Biology 98 (4): 1256–1264. doi:10.1083/jcb.98.4.1256. PMID 6371019. 
  9. ↑ Marsh, K.; Howard, R. J. (10 January 1986). "Antigens induced on erythrocytes by P. falciparum: expression of diverse and conserved determinants". Science 231 (4734): 150–153. doi:10.1126/science.2417315. PMID 2417315. Bibcode: 1986Sci...231..150M. 
  10. ↑ Howard, R J; Lyon, J A; Uni, S; Saul, A J; Aley, S B; Klotz, F; Panton, L J; Sherwood, J A et al. (1 May 1987). "Transport of an Mr approximately 300,000 Plasmodium falciparum protein (Pf EMP 2) from the intraerythrocytic asexual parasite to the cytoplasmic face of the host cell membrane.". The Journal of Cell Biology 104 (5): 1269–1280. doi:10.1083/jcb.104.5.1269. PMID 2437128. 
  11. ↑ Miller, L. H.; Howard, R. J.; Carter, R.; Good, M. F.; Nussenzweig, V.; Nussenzweig, R. S. (12 December 1986). "Research toward malaria vaccines". Science 234 (4782): 1349–1356. doi:10.1126/science.2431481. PMID 2431481. Bibcode: 1986Sci...234.1349M. 
  12. ↑ Howard, RJ (1 August 1989). "Malaria: the search for vaccine antigens and new chemotherapeutic strategies". Blood 74 (2): 533–536. doi:10.1182/blood.V74.2.533.533. INIST:7332277. PMID 2665847. 
  13. ↑ Howard, RJ; Gilladoga, AD (December 1989). "Molecular studies related to the pathogenesis of cerebral malaria". Blood 74 (8): 2603–2618. doi:10.1182/blood.V74.8.2603.2603. INIST:6773267. PMID 2479423. 
  14. ↑ van Schravendijk, MR; Rock, EP; Marsh, K; Ito, Y; Aikawa, M; Neequaye, J; Ofori-Adjei, D; Rodriguez, R et al. (1 July 1991). "Characterization and localization of Plasmodium falciparum surface antigens on infected erythrocytes from west African patients". Blood 78 (1): 226–236. doi:10.1182/blood.V78.1.226.226. INIST:4327267. PMID 2070055. 
  15. ↑ Leung, L. L.; Li, W. X.; McGregor, J. L.; Albrecht, G.; Howard, R. J. (5 September 1992). "CD36 peptides enhance or inhibit CD36-thrombospondin binding. A two-step process of ligand-receptor interaction.". Journal of Biological Chemistry 267 (25): 18244–18250. doi:10.1016/S0021-9258(19)37179-0. PMID 1381367. http://www.jbc.org/cgi/pmidlookup?view=long&pmid=1381367. 
  16. ↑ Handunnetti, SM; van Schravendijk, MR; Hasler, T; Barnwell, JW; Greenwalt, DE; Howard, RJ (15 October 1992). "Involvement of CD36 on erythrocytes as a rosetting receptor for Plasmodium falciparum-infected erythrocytes.". Blood 80 (8): 2097–104. doi:10.1182/blood.V80.8.2097.2097. PMID 1382720. 
  17. ↑ Howard, Russell J. (June 1992). "Asexual deviants take over". Nature 357 (6380): 647–648. doi:10.1038/357647a0. PMID 1614513. Bibcode: 1992Natur.357..647H. 
    Slovene pronunciation: [{{{1}}}]Thai pronunciation: [{{{1}}}]Neukirch, Jürgen; Schmidt, Alexander; Wingberg, Kay (2000), Cohomology of Number Fields, Grundlehren der Mathematischen Wissenschaften, 323, Berlin: Springer-Verlag, ISBN 978-3-540-66671-4 Template:EscapePersian pronunciation: [{{{1}}}]{| class="wikitable" width="100%"

    ! rowspan="3" colspan="2" width="14%" style="border-bottom:2px solid grey;" | Date/Time (UTC) ! Configuration ! Serial number ! Launch site ! Outcome |-

    |style="text-align:center;background-color:#e3e9e9;" | Payload |style="text-align:center;background-color:#e3e9e9;" | Separation orbit |style="text-align:center;background-color:#e3e9e9;" | Operator |style="text-align:center;background-color:#e3e9e9;" | Function |- | colspan="4" style="text-align:center;background-color:#e4dfdf;border-bottom:2px solid grey;" | Remarks |-

    Parameter 1=time required!
    Documentation[view] [edit] [history] [purge]

    This is a navigational template created using {{navbox}}. It can be transcluded on pages by placing {{Russell J. Howard}} below the standard article appendices.

    Initial visibility

    This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.

    To change this template's initial visibility, the |state= parameter may be used:

    • {{Russell J. Howard|state=collapsed}} will show the template collapsed, i.e. hidden apart from its title bar.
    • {{Russell J. Howard|state=expanded}} will show the template expanded, i.e. fully visible.

    Templates using the classes class=navbox ({{navbox}}) or class=nomobile ({{sidebar}}) are not displayed in article space on the mobile web site of English Wikipedia. Mobile page views accounted for 60% to 70% of all page views from 2020 through 2025. Briefly, these templates are not included in articles because 1) they are not well designed for mobile, and 2) they significantly increase page sizes—bad for mobile downloads—in a way that is not useful for the mobile use case. You can review/watch phab:T124168 for further discussion.

    TemplateData

    A navigational box that can be placed at the bottom of articles.

    Template parameters[Edit template data]

    ParameterDescriptionTypeStatus
    Statestate

    The initial visibility of the navbox

    Suggested values
    collapsed expanded autocollapse
    		Stringsuggested

    Template transclusions

    Transclusion maintenance
    Check completeness of transclusions
    The above documentation is transcluded from Template:Navbox documentation. (edit | history)
    Hawaiian pronunciation: [{{{1}}}]German pronunciation: [{{{1}}}]Dutch pronunciation: [{{{1}}}]Belarusian pronunciation: [{{{1}}}]Catalan pronunciation: [{{{1}}}]{{{1}}}Mongolian pronunciation: [{{{1}}}]Javanese pronunciation: [{{{1}}}]☒N Not doneLatin pronunciation: [{{{1}}}]

    | rowspan="1" colspan="2" style="border-top:2px solid #aabbcc;" |

    | style="border-top:2px solid #aabbcc;" | | style="border-top:2px solid #aabbcc;" | | style="border-top:2px solid #aabbcc;" | | style="border-top:2px solid #aabbcc;" |

    |-

    |-

    Vietnamese pronunciation: [{{{1}}}]Piedmontese pronunciation: [{{{1}}}]Slovak pronunciation: [{{{1}}}]text-align: auto;Expression error: Unrecognized punctuation character "{"./Expression error: Unrecognized punctuation character "{". (age Expression error: Unrecognized punctuation character "{".–Expression error: Unrecognized punctuation character "{".)Occitan pronunciation: [{{{1}}}]data-sort-value="" style="background: #ececec; color: #2C2C2C; vertical-align: middle; font-size: smaller; text-align: center; " class="table-na" | VariesHejazi pronunciation: [{{{1}}}]Spanish pronunciation: [{{{1}}}]Portuguese pronunciation: [{{{1}}}]Irish pronunciation: [{{{1}}}]Mayan pronunciation: [{{{1}}}]Nahuatl pronunciation: [{{{1}}}]Kyrgyz pronunciation: [{{{1}}}]Scottish Gaelic pronunciation: [{{{1}}}]Ukrainian pronunciation: [{{{1}}}]Burmese pronunciation: [{{{1}}}]Hindi pronunciation: [{{{1}}}]checkY DoneTo do To doRussian pronunciation: [{{{1}}}]Greek pronunciation: [{{{1}}}]Green tickYDanish pronunciation: [{{{1}}}]Northern Sami pronunciation: [{{{1}}}]Mandarin pronunciation: [{{{ipa}}}]Cantonese pronunciation: [{{{1}}}]Entry from Russell J. Howard from TCI Europe, retrieved on {{{Date}}}
    Documentation[view] [edit] [history] [purge]

    This is a navigational template created using {{navbox}}. It can be transcluded on pages by placing {{Russell J. Howard}} below the standard article appendices.

    Initial visibility

    This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.

    To change this template's initial visibility, the |state= parameter may be used:

    • {{Russell J. Howard|state=collapsed}} will show the template collapsed, i.e. hidden apart from its title bar.
    • {{Russell J. Howard|state=expanded}} will show the template expanded, i.e. fully visible.

    Templates using the classes class=navbox ({{navbox}}) or class=nomobile ({{sidebar}}) are not displayed in article space on the mobile web site of English Wikipedia. Mobile page views accounted for 60% to 70% of all page views from 2020 through 2025. Briefly, these templates are not included in articles because 1) they are not well designed for mobile, and 2) they significantly increase page sizes—bad for mobile downloads—in a way that is not useful for the mobile use case. You can review/watch phab:T124168 for further discussion.

    TemplateData

    A navigational box that can be placed at the bottom of articles.

    Template parameters[Edit template data]

    ParameterDescriptionTypeStatus
    Statestate

    The initial visibility of the navbox

    Suggested values
    collapsed expanded autocollapse
    		Stringsuggested
    The above documentation is transcluded from Template:Navbox documentation. (edit | history)
    Chambers, Robert; Thomson, Thomas Napier (1857). "[[s:A biographical dictionary of eminent Scotsmen/|]]". A Biographical Dictionary of Eminent Scotsmen. Glasgow: Blackie and Son. {{{1}}}Polish pronunciation: [{{{1}}}]Malagasy pronunciation: [{{{1}}}]Japanese pronunciation: [{{{1}}}]Armenian pronunciation: [{{{1}}}]Czech pronunciation: [{{{1}}}]∶Manx pronunciation: [{{{1}}}]http://www.iucnredlist.org/apps/redlist/details/full/{{{1}}}/0 Alemannic German pronunciation: [{{{1}}}]Tagalog pronunciation: [{{{1}}}]Egyptian Arabic pronunciation: [{{{1}}}]French pronunciation: ​[{{{1}}}]Error: Invalid time.In progress In progressPalomares, M. L. D. and Pauly, D., eds. (2011). "{{{1}}} {{{2}}}" in SeaLifeBase. April 2011 version.Turkish pronunciation: [{{{1}}}]Finnish pronunciation: [{{{1}}}]Froese, Rainer and Pauly, Daniel, eds. (2006). "{{{1}}} {{{2}}}" in FishBase. April 2006 version.

    |- | ... | — | — | — | — | — | —

    |-Old Norse pronunciation: [{{{1}}}]Salish pronunciation: [{{{1}}}]Basque pronunciation: [{{{1}}}]{{{1}}}data-sort-value="" style="background: #ececec; color: #2C2C2C; vertical-align: middle; font-size: smaller; text-align: center; " class="table-na" | UnreleasedNorwegian pronunciation: [{{{1}}}] (aged {{{4}}})Hungarian pronunciation: [{{{1}}}]Quechua pronunciation: [{{{1}}}]Arabic pronunciation: [{{{1}}}]Punjabi pronunciation: [{{{1}}}]Afrikaans pronunciation: [{{{1}}}]Romanian pronunciation: [{{{1}}}]Hebrew pronunciation: [{{{1}}}][INVALID OR MISSING PARAMETER IN TEMPLATE Russell J. Howard]Uto-Aztecan pronunciation: [{{{1}}}]Tamil pronunciation: [{{{1}}}]Hindustani pronunciation: [{{{1}}}]Swedish pronunciation: [{{{1}}}]Kazakh pronunciation: [{{{1}}}]
    Lao pronunciation: [{{{1}}}]Tibetan pronunciation: [{{{1}}}]Khmer pronunciation: [{{{1}}}]data-sort-value="" style="vertical-align:middle; text-align:center" class="table-na" | —{{{1}}}Welsh pronunciation: [{{{1}}}]Incomplete Partially doneAthabaskan pronunciation: [{{{1}}}]Māori pronunciation: [{{{1}}}]IPA: [{{{1}}}]Bulgarian pronunciation: [{{{1}}}]Korean pronunciation: [{{{1}}}]Icelandic pronunciation: ​[{{{1}}}]Sanskrit pronunciation: [{{{1}}}]Bengali pronunciation: [{{{1}}}]Indonesian pronunciation: [{{{1}}}]Serbo-Croatian pronunciation: [{{{1}}}]CROSBI {{{1}}}Howard, R.J.; Pasloske, B.L. (October 1993). "Target antigens for asexual malaria vaccine development". Parasitology Today 9 (10): 369–372. doi:10.1016/0169-4758(93)90085-t. PMID 15463671. 
  18. ↑ Pasloske, Brittan L.; Howard, Russell J. (February 1994). "Malaria, the red cell, and the endothelium". Annual Review of Medicine 45 (1): 283–295. doi:10.1146/annurev.med.45.1.283. PMID 8198384. 
  19. ↑ 19.0 19.1 Baruch, Dror I.; Pasloske, Britten L.; Singh, Hardeep B.; Bi, Xiahui; Ma, Xin C.; Feldman, Michael; Taraschi, Theodore F.; Howard, Russell J. (1995). "Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes". Cell 82 (1): 77–87. doi:10.1016/0092-8674(95)90054-3. PMID 7541722. 
  20. ↑ Aley, S B; Sherwood, J A; Howard, R J (1 November 1984). "Knob-positive and knob-negative Plasmodium falciparum differ in expression of a strain-specific malarial antigen on the surface of infected erythrocytes.". Journal of Experimental Medicine 160 (5): 1585–1590. doi:10.1084/jem.160.5.1585. PMID 6208311. 
  21. ↑ Baruch, DI; Ma, XC; Singh, HB; Bi, X; Pasloske, BL; Howard, RJ (1 November 1997). "Identification of a region of PfEMP1 that mediates adherence of Plasmodium falciparum infected erythrocytes to CD36: conserved function with variant sequence.". Blood 90 (9): 3766–75. doi:10.1182/blood.V90.9.3766. PMID 9345064. 
  22. ↑ Willem P.C. Stemmer
  23. ↑ 23.0 23.1 Zaffaroni Announces New Start-Up Company – Maxygen, Inc.
  24. ↑ 24.0 24.1 Maxygen, Inc. Raises $110 Million In Initial Public Offering of Its Common Stock
  25. ↑ 25.0 25.1 DuPont To Acquire Maxygen Subsidiary Verdia
  26. ↑ 26.0 26.1 Maxygen Announces Launch of Wholly Owned Chemicals Subsidiary, Codexis, Inc.
  27. ↑ Maxygen and Astellas Announce Global Agreement to Develop New Therapies for Autoimmune Diseases and Transplantation.
  28. ↑ "Kinghorn Centre for Clinical Genomics Staff". Organisation Website. Garvan Institute. http://www.garvan.org.au/research/clinical-genomics/@@staff-profiles. 
  29. ↑ Durkin, Patrick. "Russell Howard: scientist, entrepreneur, CEO". Magazine. Australian Financial Review. http://www.afr.com/p/boss/russell_howard_scientist_entrepreneur_DZ3lOfKd4QnALP0UZ385mM. 
  30. ↑ Howard, Russell; Grant, Bruce; Fock, Heinrich (2008-06-28). "Storage and structural products formed during photosynthesis in the siphonous alga Caulerpa simpliciuscula (Chlorophyceae)". Journal of Phycology 13 (4): 340–345. doi:10.1111/j.1529-8817.1977.tb02938.x. https://www.researchgate.net/publication/230260017. 
  31. ↑ "Maxygen Lands Grant to Pursue Malaria vaccine". https://www.bizjournals.com/sanfrancisco/stories/2001/10/15/newscolumn1.html. 
  32. ↑ Howard, R J; Uni, S; Aikawa, M; Aley, S B; Leech, J H; Lew, A M; Wellems, T E; Rener, J et al. (1 October 1986). "Secretion of a malarial histidine-rich protein (Pf HRP II) from Plasmodium falciparum-infected erythrocytes.". The Journal of Cell Biology 103 (4): 1269–1277. doi:10.1083/jcb.103.4.1269. PMID 3533951. 
  33. ↑ Wellems, T. E.; Howard, R. J. (1 August 1986). "Homologous genes encode two distinct histidine-rich proteins in a cloned isolate of Plasmodium falciparum.". Proceedings of the National Academy of Sciences 83 (16): 6065–6069. doi:10.1073/pnas.83.16.6065. PMID 3016741. Bibcode: 1986PNAS...83.6065W. 
  34. ↑ Rapid Diagnostic Test Information: Malaria Diagnostic Overview.



Retrieved from "https://handwiki.org/wiki/index.php?title=Biography:Russell_J._Howard&oldid=4223056"